Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 24;44(10):2004–2018. doi: 10.1038/s41401-023-01101-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Survival rate of each group after 5 days past doxorubicin injection. b Echocardiographic assessment of mice in each group 5 days after doxorubicin administration. c cTnI concentration in each group at 3 days post doxorubicin injection. d HW/TL in each group at day 5 post doxorubicin injection. e qRT-PCR analysis of antioxidant enzyme gene expression, including GPX, CAT, and PRDX. f, g MDA content and SOD activity in each group. h Representative immunohistochemistry and immunofluorescence images (×400 magnification) in each group with indicated staining. i Statistical analysis of immunohistochemistry and immunofluorescence presented in h. The results of immunohistochemistry are shown as positive area per total area (%Area). The results of immunofluorescence are presented as the mean fluorescence intensity. j Western blotting and statistical analysis of Bcl-2 and Bax. GAPDH was used as an internal control. ns, non-significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Scaler bar: 100 μm.